Wiley Bros. Aintree Capital, LLC Zai Lab LTD Transaction History
Wiley Bros. Aintree Capital, LLC
- $12.5 Billion
- Q2 2025
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Zai Lab LTD stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 6,469 shares of ZLAB stock, worth $218,328. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,469Holding current value
$218,328% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ZLAB
# of Institutions
170Shares Held
38.6MCall Options Held
150KPut Options Held
201K-
Capital World Investors Los Angeles, CA6.04MShares$204 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY5.54MShares$187 Million2.97% of portfolio
-
Clearbridge Investments, LLC New York, NY4.01MShares$135 Million0.12% of portfolio
-
Janus Henderson Group PLC London, X02.2MShares$74.2 Million0.04% of portfolio
-
Bamco Inc New York, NY1.59MShares$53.6 Million0.16% of portfolio
About Zai Lab Ltd
- Ticker ZLAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,908,704
- Market Cap $3.3B
- Description
- Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...